Background and objective: During routine follow up, there is no specific predictor to ascertain relapse after standard first line chemotherapy in diffuse large cell lymphoma. Therefore, this study was designed to assess the prognostic significance of the ratio between absolute lymphocyte and monocyte counts (LMR) in the peripheral blood to verify relapse in diffuse large B cell lymphoma. Patients and methods: A total of 139 patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) were evaluated and treated with CHOP or R-CHOP between the years 2009 and 2016. Three months following completion of first line therapy, Lymphocyte/monocyte ratio (LMR) was calculated from the routine automated complete blood cell count (CBC) attained a plateau after the bone marrow recovery after first line chemotherapy. The absolute lymphocyte count/absolute monocyte count ratio (LMR) was calculated by dividing the ALC by the AMC. Results: ROC curve analysis of 139 patients established 2.8 as cutoff point of LMR for relapse with AUC of 0.97 (95% CI 0.93 -0.99, P ≤ 0.001). Cox regression analysis was performed to identify factors predicting relapse. In univariate regression analysis, ALC (95% CI 0.003 -0.03, p ≤ 0.001), AMC (95% CI 15.4 -128.8, p ≤ 0.001), LMR (95% CI 0.001 -0.01, p ≤ 0.001), and LDH (95% CI 0.1 -0.5, p ≤ 0.001) following completion of therapy are significant factors for relapse. Other significant factors for relapse are Ann Arbor stage (95% CI 1.1 -6.9, P = 0.03), extranodal sites (95% CI 1.2 -6.1, P = 0.01), age (95% CI 1.3 -6.5, P = 0.01) and treatment of CHOP protocol (95% CI 0.05 -0.6, P = 0.007). In a multivariate analysis LMR following completion of therapy was predictive for relapse (95% CI 0.001 -0.2, P = 0.005). ALC was also significant in multivariate analysis (95% CI 0.01 -0.8, P = 0.03). LDH following completion of therapy (95% CI 0.2 -14.9, P = 0.5), AMC following completion of therapy (95% CI 0.3 -43.1, P = 0.3), age (95% CI 0.9 -205.4, P = 0.06), extra-nodal sites (95% CI 0.04 -9.8, P = 0.8), Ann Arbor stage (95% CI 0.3 -28.7, P = 0.3), and Treatment of CHOP protocol (95% CI 0.01 -2.4, P = 0.2) were not statistically significant. Conclusion: This study observed that LMR assessed after first line chemotherapy during routine follow up is an independent predictor of relapse and clinical outcome in DLBCL patients. LMR at follow up can be used a simple inexpensive biomarker to alert clinicians for relapse during follow up after standard first line chemotherapy in DLBCL patients.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoid neoplasm as it represents 25% -30% of all newly diagnosed cases of adult Non-Hodgkin lymphoma (NHL) [1] . Although it is an aggressive type of lymphoma, it is potentially curable.
The routine addition of rituximab therapy improved the overall survival of patients with DLBCL. However, approximately one-third of the patients develop relapsed/refractory disease that remains a major cause of morbidity and mortality [2] .
Clinical outcome in DLBCL patients treated with standard therapy is assessed by risk factors before treatment implementation, such as the international prognostic index (IPI) [3] , Immunohistochemistery-based detection [4] [5] or gene expression profiling [6] [7] .
Immunodeficiency is one of the strongest risk factors of non-Hodgkin lymphoma [8] . Gene-expression profiling (GEP) studies showed a relationship between lymphoma biology and the host immune system, and suggested that gene signatures related to nonmalignant tumor microenvironment played an important role in the clinical outcomes of patients with NHL [9] [10] [11] .
In spite of the fact that specific gene signatures of host immunity can predict prognosis of DLBCL patients, it is impractical for application on routine basis due to coast and technical limitation. Therefore, a large number of studies have therefore focused on the search for surrogate biomarkers which are immunologically relevant and can serve as prognostic factors [11] [12] [13] .
During follow up after standard therapy in DLBCL, lactic dehydrogenase (LDH) is an inexpensive factor that helps to identify patients who might require further evaluation for relapse. LDH has been reported to have a sensitivity of 42% and a specificity of 85% to predict relapse during follow-up [14] . 
Patients & Methods

Study Objective
The primary aim of the study was to assess the ability of the LMR after completion of first-line therapy to predict relapse of DLBCL. We also evaluated whether the LMR affected overall survival (OS) and disease-free survival (DFS); we performed a landmark analysis commencing 3 months after completion of chemotherapy when the patients were in complete remission which was confirmed by CT scans.
Following completion of first line therapy, we calculated LMR from the routine automated complete blood cell count (CBC) attained a plateau after the bone marrow recovery after first line chemotherapy. In our routine follow up CBC was done after 3 months after completion of chemotherapy. Therefore, we used the LMR data from the 3-month follow-up visits.
The absolute lymphocyte count/absolute monocyte count ratio (LMR) was calculated by dividing the ALC by the AMC.
Response and relapse criteria were based on the criteria from the International Harmonization Project [18] . Overall survival (OS) was measured from the day following completion of first-line therapy until the date of death from any cause, or date of the last follow-up. Disease free survival (DFS) measured from the day following completion of first-line therapy until the date of first lymphoma relapse, death from any cause, or date of the last follow-up.
Follow-up procedures usually included a physical examination, blood tests 
Statistical Analysis
All statistical analyses were performed using SPSS statistical software (version 21). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal LMR cutoffs yielding the maximal combined sensitivities and specificities.
Correlations of the ALC, AMC, and LMR with clinical parameters were evaluated using the chi-square or Fisher's exact test. OS and PFS were analyzed using Kaplan-Meier curves, which were compared using the log-rank test. Cox regression model was applied in both univariate and multivariate analyses to prognostic variables to predict relapse. Categorical variables were compared using the chi-square test. P value of <0.05 was considered statistically significant.
Results
Patient Characteristics
Retrospectively, we analyzed data of a total 139 DLBCL patients in this study. Table 1 .
Median follow up was 48 months (range 16 -84 months). Among 139 patients, 39 patients (28.1%) had relapsed disease. Early relapse defined as relapse occurred less than 12 month.
Fourteen patients (10.07%) showed early relapsed disease with median LMR 1.7 (range 1.3 -2.1).
Cut off Values for the ALC, AMC, and LMR as Marker for Relapse
The choice of the best cutoff in predicting relapse was selected by receiver operating characteristic (ROC) curves and calculated areas under the curves (AUCs).
The most discriminative cutoff value of ALC was 1170 cells/UL with AUC of 
Relapse Rate by Prognostic Factors
Relapse rate was higher in patients with LMR < 2.8, ALC < 1170, AMC ≥ 445 and higher LDH after completion of chemotherapy (94.9% P ≤ 0.001, 84.6% P ≤ 0.001, 79.5% p ≤ 0.001, 59% p ≤ 0.001 respectively). Also, the relapse rate was (Table 3) . Table 4 .
Prognostic Factors Predict Relapse
Survival Analysis
Disease free survival (DFS) and overall survival (OS) were analyzed according to 
Discussion
In spite of addition of anti-CD 20 monoclonal antibody rituximab in treatment of diffuse large B cell lymphoma, significant percentage of patients relapsed and that remain a major cause of mortality and morbidity [19] .
The main objective of follow-up is to detect early relapse in order to improve Comprehensive Cancer Network [20] . Moreover, follow-up every 3 months for 1 year, every a half year for two years and afterward once per year in NHL patients was recommended by the European Society of Medical Oncology [21] .
Careful history, physical examination and good clinical judgment are the most important items in monitoring patients after treatment [18] . More than 80% of relapse can be determined by patients or physicians, so regular surveillance CT scans is unsatisfactory for prediction of relapse [22] [23] . Furthermore, false positive results are frequent and unnecessary biopsies or additional scans will be done without need [24] .
In asymptomatic DLBCL patients who achieved a complete response, routine assessment of lactic dehydrogenase is not recommended [25] . So, currently both ESMO and NCCN recommended follow up by blood counts and repeating CT scans only when clinically indicated [26] .
Clinical outcome in DLBCL patients are assessed by risk factors identified be- The LMR biomarker reflects the status of both immune homeostasis and the tumor microenvironment after treatment. LMR was shown to be an independent prognostic marker in patients with DLBCL patients [33] .
In the current study, the choice of best cutoff values of ALC, AMC and LMR was significantly correlated with early relapse in both univariate and multivariate analysis [26] . Our result was in accordance with those previous studies. On the other hand, YAMAUCHI et al. 2015 reported that low lymphocytes monocytes ratio was not predictive for disease relapse of advanced DLBCL [35] .
In the present study, we observed that patients with high LMR ≥ 2. 
Conclusion
The current study is retrospective with relatively low number of patients to allow confirmation of diagnosis. So to minimize these biases we selected only patients with de novo DLBCL treated with standard first line chemotherapy. In addition, receiver operating characteristic curves and area under the curve were used to determine the best ALC, AMC, LMR cutoff value. This study observed that LMR assessed after first line chemotherapy during routine follow up is an independent predictor of relapse and clinical outcome in DLBCL patients. LMR at follow up can be used a simple inexpensive biomarker to alert clinicians of relapse during follow up after standard first line chemotherapy in DLBCL patients.
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